Back to Home

Accessibility Statement

Fully accessible

Our Commitment

MDL8MND has made its website fully accessible in accordance with the Web Content Accessibility Guidelines (WCAG) 2.1 Level AA. This has been confirmed through PageSpeed testing.

Accessibility Features

This website offers the following features to improve accessibility:

  • Accessibility toolbox (bottom left) with the following options:
    • Stop animations – Disables all moving elements for people with vestibular disorders or epilepsy
    • High contrast – Increases color contrast for better readability
    • Larger text – Increases text size
    • Standard cursor – Shows the normal mouse pointer instead of the custom cursor
  • Support for system setting "Reduced Motion" (prefers-reduced-motion)
  • Skip link to bypass navigation
  • Semantic HTML structure with ARIA labels
  • Keyboard navigation for all interactive elements
  • Focus indicators for keyboard users
  • Alt texts for informative images

External Content

The following external content is not under our direct control:

  • Embedded SoundCloud Player – The accessibility of the player is beyond our control
  • Visual Effects – Glitch effects and scanlines are purely decorative and can be disabled via the toolbox

Technical Specifications

The accessibility of this website is based on the following technologies:

  • HTML5 with semantic elements
  • WAI-ARIA for enhanced accessibility
  • CSS with support for user settings
  • JavaScript for interactive accessibility features

The website has been tested with current versions of:

  • Chrome, Firefox, Safari, Edge
  • VoiceOver (macOS/iOS)
  • NVDA (Windows)

Feedback & Contact

We welcome feedback on the accessibility of this website. If you encounter barriers or have suggestions for improvement, please contact us:

Email: contact@catharsys.at
Subject: Accessibility MDL8MND

We aim to respond within 5 business days.

This statement was created in accordance with EU Directive 2016/2102 on the accessibility of websites and mobile applications.

Date of this statement: February 2026
Last review: February 2026